MAPT and Alzheimer disease: P-tau217 may be even more accurate than p-tau181 at predicting Aβ-PET positivity, correlating with tau-PET [25], and correctly differentiating AD from other forms of dementia in CSF and plasma in up to 96% of cases [26,27,28].